Mechanisms of acquired resistance to ERK1/2 pathway inhibitors (Q38007869)

26 August 2017

title

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors (English)

1 reference

26 August 2017

A S Little

1

1 reference

26 August 2017

P D Smith

series ordinal

2

1 reference

26 August 2017

S J Cook

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

7 May 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

32

1 reference

26 August 2017

issue

10

1 reference

26 August 2017

page(s)

1207-1215

1 reference

The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Ras oncogenes: split personalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Tumour cell survival signalling by the ERK1/2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Analysis of the transcriptional program induced by Raf in epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Regulation of Raf-1 by direct feedback phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Regulation of epidermal growth factor receptor signaling by phosphorylation of the ras exchange factor hSOS1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Biology using engineering tools: the negative feedback amplifier

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Targeting the RAS pathway in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

BRAF mutations in hairy-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

MEK1 mutations confer resistance to MEK and B-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Oncogenic activating mutations are associated with local copy gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Regulation of cyclin D1 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Raf-Induced Proliferation or Cell Cycle Arrest Is Determined by the Level of Raf Activity with Arrest Mediated by p21Cip1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Senescence of human fibroblasts induced by oncogenic Raf.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/ONC.2012.160

21 January 2018

Identifiers

DOI

10.1038/ONC.2012.160

1 reference

Dimensions Publication ID

26 August 2017

1007888310

0 references

1 reference